[ad_1]
The European Medicines Agency has approved two new treatments for Covid-19: an antibody drug and an arthritis drug that has been shown to “reduce” inflammation associated with the virus.
The first drug, Xevudy, made by GlaxoSmithKline and Vir Biotechnology, is recommended to treat the virus in adults and adolescents over 12 years of age who weigh at least 40 kg who do not need additional oxygen and who are at increased risk of disease. . “
Xevudy is the third monoclonal antibody treatment approved for use in the European Union after Regkirona and Ronapreve.
The second drug, Kineret, from the Swedish company Sobi is an immunosuppressive drug currently used to treat inflammatory conditions.
In patients with COVID-19, the drug is considered to reduce associated inflammation [the virus] Thus reducing lower airway damage, preventing acute respiratory failure.”
Recommended for adult covid patients with pneumonia who require supplemental oxygen and are “at risk of developing acute respiratory failure”.
The regulator has so far approved six treatments for Covid-19, including the latest additions to the list. It is also currently studying approval of several other treatments in an attempt to reduce the effect of the rapidly spreading variant of Omicron. Those under consideration include Paxlovid from Pfizer and Lagevrio from Merck.
On Thursday, the head of the UK’s antiviral task force said he expected these two drugs to be available for use there during the winter period.
According to the European Commission, the Omicron variant will become dominant in the European Union by mid-January.
|
Sources 2/ https://news.google.com/__i/rss/rd/articles/CBMiPGh0dHBzOi8vd3d3LnJ0LmNvbS9uZXdzLzU0MzQzNi1ldS1hcHByb3Zlcy1jb3ZpZC10cmVhdG1lbnRzL9IBAA?oc=5 The mention sources can contact us to remove/changing this article |
[ad_2]